FEATURE ARTICLE
Recently, major developments in the treatment of colon cancer have emerged. These developments include improvements in surgical technique and staging and the introduction of new molecularly targeted pharmacologic agents. Improvements in surgical management involve enhanced staging techniques, allowing more accurate determination of risk of recurrence. Newer agents, such as oxaliplatin, cetuximab, and bevacizumab, now are approved for the treatment of colon cancer. The data associated with use of oxaliplatin in adjuvant and metastatic settings continue to mature; survival benefits are expected to become more fully apparent in the next two years. Bevacizumab, a monoclonal antibody that neutralizes vascular endothelial growth factor, when combined with irinotecan, 5-fluorouracil, and leucovorin (IFL), was superior to IFL alone in achieving median and progression-free survival. Cetuximab, a monoclonal antibody directed against the epidermal growth factor receptor, when given in combination with irinotecan, achieved an increased objective response and increased time to progression, compared with cetuximab alone, in patients refractory to irinotecan-containing regimens. In addition to surgical and pharmacologic developments, the recognition that genetics and molecular markers play an important role in carcinogenesis has heightened research to integrate this knowledge into practice. Nurses play a pivotal role in the care of patients with colon cancer and must be conversant in the new advances in treatment.
A lthough colon cancer is preventable and curable, it ranks third in cancer incidence and mortality in the United States. In 2004, 106,370 patients were expected to develop cancer of the colon and 56,730 to die from colon and rectal cancers combined (American Cancer Society, 2004a , 2004b . New therapeutic options may improve these statistics as they are integrated into standard practice. This article describes recent advances in chemotherapy that may help to prevent recurrence and manage advanced disease in patients with colon cancer. Potential side effects, specific nursing assessments, symptom management, and patient and family education will be discussed.
Surgical Staging
The most important prognostic indicator for patients with colon cancer is stage of disease at diagnosis (see Table 1 ). Accurate staging is essential to the appropriate therapeutic recommendation. Stage is determined by the depth of tumor penetration or invasion of the bowel wall, the number of lymph nodes involved, and the presence or absence of distant metastases. In 2002, the American Joint Committee on Cancer revised staging for colon cancer to reflect risk of recurrence and differences in survival for patients with stages II and III disease. Projected survival for patients with stage III disease differs significantly depending on substages. Additionally, some patients with stage II disease (IIA involves a T3 lesion, whereas stage IIB involves a T4 lesion) are at high risk for recurrence. Such patients often are offered entry into adjuvant therapy clinical trials. However, in 2004, the American Society of Clinical Oncology did not support routine use of adjuvant chemotherapy for patients with stage II colon cancer, based on direct evidence from randomized, controlled trials (Benson, Catalano, Meropol, O'Dwyer, & Giantonio, 2003) .
Adjuvant therapy is designed to reduce the likelihood of disease recurrence. The identification of patients who may benefit from adjuvant therapy relies on sampling an adequate number of lymph nodes. In reviewing patient outcomes related to surgical sampling of lymph nodes Genentech, Inc., and , in 2003 and Society.) in one adjuvant trial for high-risk patients, Le Voyer et al. (2003) found that survival decreased with increasing numbers of involved lymph nodes. Survival increased as more lymph nodes were analyzed and accurate staging was identified. Swanson, Compton, Stewart, and Bland (2003) demonstrated that in patients with T3, N0 lesions, the five-year survival rate was 64% in those with only one or two lymph nodes removed and examined, compared with 86% when more than 25 lymph nodes were removed and examined. As a result of these and other trials, the current standard is examination of a minimum of 13 lymph nodes to identify a T3 colon cancer lesion as node negative (Swanson et al.) . Thus, adequate lymph node sampling permits accurate staging, and patients at risk for recurrence can be offered adjuvant chemotherapy.
In addition to enhanced surgical staging techniques, a better understanding of the molecular basis for colon cancer also has helped to better target adjuvant treatment recommendations. For example, patients with poor prognosis genetic mutations may be identified as candidates for adjuvant therapy. Several national clinical trials groups, such as the Eastern Clinical Oncology Group, are developing prospective research protocols that will help identify risk conferred by molecular flaws, such the presence of the 18q allele and microsatellite instability status in tumors of patients with stage II colon cancer (National Cancer Institute, 2004) . This information will help identify patients appropriate for adjuvant therapy.
Chemotherapy in Colon Cancer

5-Fluorouracil and Leucovorin
Much has changed since the 1960s, when the antimetabolite 5-fluorouracil (5-FU) was used as a single agent in the treatment of advanced colon cancer, and since the 1980s, when 5-FU in combination with leucovorin (LV) demonstrated improved survival over single-agent 5-FU (Skibber, Minsky, & Hoff, 2001 ). More recent data have shown that infusional administration is significantly less toxic than and as effective as bolus administration (Penland & Goldberg, 2004) .
Irinotecan
In 1996, the topoisomerase I inhibitor irinotecan received approval from the U.S. Food and Drug Administration (FDA) for secondline treatment of advanced colon cancer; approval for a first-line indication followed in 2000 because irinotecan demonstrated superiority to 5-FU/LV in clinical trials (Saltz et al., 2000) . Figure 1 provides a schematic of the infusional 5-FU/LV regimen. Two major trials evaluated irinotecan in patients with stage IV colon cancer. The U.S. trial (Saltz et al., 2000) compared 5-FU/LVvia bolus injections and irinotecan (IFL), and the European trial used irinotecan and infusional administration of 5-FU (Douillard et al., 2000) . Median overall survivals were 14.8 months for patients receiving IFL and 17.4 months for those receiving the infusional regimen, compared with 12.6 months for 5-FU/LV alone and 14.1 months for the bolus and infusional regimens, respectively. Figure 2 depicts the treatment schema for the regimen used in the study by Douillard et al. The dose-limiting toxicities of single-agent irinotecan are diarrhea and neutropenia. When irinotecan is combined with 5-FU/LV in the IV bolus combination, the incidence of these side effects increases (Saltz et al., 2000) , requiring significant nursing interventions.
Oxaliplatin
Oxaliplatin, a third-generation platinum analog, received FDA approval for secondline treatment in 2002, and in 2004, first-line treatment of patients with metastatic disease and adjuvant treatment of patients with stage III colon cancer following complete surgical resection, in combination with infusional 5-FU/LV (Center for Drug Evaluation and Research, 2004) . Regimens integrating oxaliplatin into the 5-FU/LV regimen (known as FOLFOX) have shown promising results. FOLFOX4 is depicted in Figure 3 . FDA approval was based on the results of N9741, a large, national, cooperative clinical trial, which demonstrated that median time to progression, overall response rate, and median survival for patients with advanced colon cancer were significantly higher in the FOLFOX4 arm than in the IFL arm or in the irinotecan combined with oxaliplatin (IROX) arm (Goldberg et al., 2003 . (See Table  2 for comparison.) Andre, Boni, et al. (2004) described the results of their large (N = 2,246), randomized, multinational trial known as the Multicenter International Study of Oxaliplatin/5-Fluorouracil/Leucovorin in the Adjuvant Treatment of Colon Cancer (MOSAIC), comparing FOLFOX4 with infusional 5-FU/LV in patients with resected stage II (40%) and stage III (60%) colon cancer. In the trial, at a median follow-up of three years, disease-free survival was 78.2% in the group given 5-FU/LV and oxaliplatin and 72.9% in the 5-FU/LV group. This corresponds to a 23% decrease in the risk of recurrence for patients receiving oxaliplatin. An analysis of individual patient data from 15 randomized trials confirmed that three-year disease-free survival and traditional five-year overall survival are correlated highly, making three-year disease-free survival an excellent end point for adjuvant trials .
Data are pending from the National Surgical Adjuvant Breast and Bowel Project (NSABP) C-07 trial which compared 5-FU/LV to FLOX (which uses bolus 5-FU) in patients with stage II or III colon cancer in the adjuvant setting. Saltz, Niedzwiecki, et al. (2004) reported results of the Cancer and Leukemia Group B-C89803 trial, which compared 5-FU/LV and IFL regimens. IFL was found to have no clinical benefit in stage III colon cancer in the adjuvant setting and is not recommended for use.
Bevacizumab and Cetuximab
Because malignant tumors cannot grow beyond 1-2 mm without establishing a new blood vessel system, agents are being studied which have the capacity to neutralize growth factors, such as vascular endothelial growth factor (VEGF 
FIGURE 1. INFUSIONAL 5-FLUOROURACIL/LEUCOVORIN REGIMEN
Note. Based on information from de Gramont et al., 1997.
5-FU-5-fluorouracil
agents is based on evidence that colon cancer is a disease of sequential genetic mutations involving growth factors responsible for cellular growth and proliferation. Two mutations are associated with increased production of VEGF, which is needed for the development of neovasculature that nourishes a growing tumor. These mutations include (a) mutation of the oncogene k-ras and (b) mutation of p53, a tumor-suppressor gene. In addition, most colon cancers overexpress epidermal growth factor receptors (EGFRs), resulting in the release of VEGF and the suppression of apoptosis (programmed cell death) for cells with irreparable DNA mutations (Wilkes & Barton-Burke, 2005 ). The process is as follows: A small tumor receives its nutrition and removes waste products by simple diffusion.
When it reaches a size of 1-2 mm, or that of a pencil point, it releases VEGF, which attaches to receptors on blood vessel endothelial cells, signaling them to proliferate and migrate to make new blood vessels to support tumor growth.
Bevacizumab is a recombinant, humanized monoclonal antibody directed against VEGF by neutralizing it before it can bind to the endothelial cell receptor. On the basis of data from Hurwitz et al. (2004) , bevacizumab received FDA approval in combination with a 5-FU-based regimen for the first-line treatment of metastatic colon cancer. Patients receiving IFL plus bevacizumab had a higher response rate (44.8% versus 34.8%) and superior median survival (20.3 months versus 15.6 months) compared with IFL alone, as shown in Table  2 (Hurwitz et al.) . Bevacizumab currently is being studied in FOLFOX4 and other combinations in the adjuvant setting (Abrams & Wolmark, 2004) .
The second drug, cetuximab, is a monoclonal antibody that blocks EGFRs on the cell surface. This prevents the stimulatory signal from the growth factor, which ordinarily would pass through the cell via signal transduction, to the cell nucleus, where the message would be transcribed, leading to cell proliferation, VEGF production, and apoptosis suppression (Wilkes & Barton-Burke, 2005 ). Based on a study of cetuximab in combination with irinotecan in patients refractory to irinotecan and with EGFR-positive tumors, the FDA approved cetuximab as a single agent or in combination with irinotecan as second-line treatment (Cunningham et al., 2004) . Patients in the experimental arm had a superior response rate (22.9% versus 10.8%) and increased overall survival (8.6 months versus 6.0 months) compared with cetuximab alone (Cunningham et al., 2004) . Clinical trials to further examine the efficacy of combining antiangiogenic agents with existing regimens are ongoing (Kabbinavar et al., 2003) . The NSABP C-08 trial will compare patients with resected stage II or III colon cancer, after stratification by number of positive nodes, to either standard treatment (FOLFOX6) or FOLFOX6 plus bevacizumab (Abrams & Wolmark, 2004; Yothers, 2004) .
The number of pharmacologic trials examining the efficacy of established and new agents alone and in combination for patients with advanced colon cancer has increased rapidly. Results of comparative clinical trials are summarized in Table 2 . Regimens in use for the treatment of advanced colon cancer are listed in Table 3 . The studies help meet the important need to make available a variety of agents with different mechanisms of action that can be combined safely without overlapping toxicities.
Capecitabine
Another agent, capecitabine, is an oral 5-FU prodrug that mimics continuous infusion 5-FU. Capecitabine is converted to 5-FU by thymidine synthase, which is more highly expressed in tumor cells than in normal tissue. Because capecitabine demonstrated efficacy equivalent to 5-FU/LV bolus or infusion, it received first-line indication in 2001 ).
Nursing Implications
Active chemotherapeutic agents, particularly when given in multidrug combinations, require sophisticated nursing management. Nurses caring for patients receiving combinations of these agents must be knowledgeable about potential side effects and interventions designed to prevent, minimize, or eliminate responses before they progress to high-severity grades and life-threatening complications. Patients and their families play a key role in symptom identification and must be aware of the importance of self-assessment and self-care. In addition, patients and their families need to be aware of when and what to report to the healthcare team to minimize the impact of side effects on quality of life, safety, and survival. Nurses are instrumental in helping patients safely receive chemotherapy.
Toxicities associated with therapy for colon cancer are general and specific to the particular agents used. In addition to the more general side effects of bone marrow suppression, nausea, and vomiting, major drug-specific toxicities include diarrhea (irinotecan) (Pharmacia Corporation, 2002); hand-foot syndrome (capecitabine) (Roche Pharmaceuticals, 2003) ; neuropathy, hypersensitivity, and extravasation-induced skin necrosis (oxaliplatin) (Sanofi-Synthelabo, 2004) ; hypertension, thrombosis, bleeding, delayed wound healing, gastrointestinal perforation (bevacizumab) (Genentech, Inc., 2004) ; and acneiform rash (cetuximab) (ImClone, Inc., and Bristol-Myers Squibb Co., 2004).
Focused patient assessment permits early identification of side effects and timely intervention that can be instrumental in preventing progression to higher toxicity grades and associated life-threatening complications. At least one clinical study indicated that patients receiving IFL without close monitoring and aggressive symptom management had significant morbidity (Rothenberg, Meropol, Poplin, Van Cutsem, & Wadler, 2001) . Table 4 identifies administration guidelines for monoclonal antibodies. Common side effects of key agents use to treat colon cancer with specific nursing interventions are outlined in Table 5 .
Diarrhea
Irinotecan can result in acute cholinergic diarrhea and delayed secretory diarrhea. IFL plus bevacizumab versus IFL (Hurwitz et al., 2004) Irinotecan plus cetuximab versus cetuximab (Cunningham et al., 2004) FOLFOX4 versus FOLFOX7 alternating with 5-FU/LV (Andre et al., 2003; deGramont et al., 2004) CapIri versus CapOx (Grothey et al., 2003) and Xelox 14. (Rothenberg et al., 2001 ).
Significant differences, p = 0.005; capecitabine: less diarrhea, nausea, vomiting, and neutropenia but more incidence of hand-foot syndrome and higher bilirubin
Patients refractory to 5-FU/LV; registration clinical trial Significant differences at 20.4 months follow-up; FOLFOX4: significantly less nausea and vomiting, diarrhea, dehydration, and febrile neutropenia but more paresthesia compared to IFL. 60% of patients in FOLFOX4 arm received second-line irinotecan, whereas only 24% of patients in IFL arm received second-line oxaliplatin because of availability. Bolus 5-FU/LV while FOLFOX4 was infusional; IFL dose reduction was necessary because of excessive early deaths in the IFL arm.
First-line indication; bevacizumab: grade 3 hypertension was easily managed; gastrointestinal perforations Second-line indication; no survival advantage was shown; grade 3 and 4 toxicities: diarrhea, asthenia, and acne-like rash were greater in the combination arm.
OPTIMOX trial intended to decrease the incidence of severe, dose-limiting neurotoxicity; first-line treatment of patients with advanced colon cancer; rates of grade 3 or 4 neutropenia were higher in FOLFOX4 arm, but thrombocytopenia was higher in FOLFOX7 arm. Can stop, then go with oxaliplatin and retain sensitivity to drug.
Irinotecan dose was reduced to 80 mg/m 2 after four deaths in first 40 patients on CapIri arm, then toxicity was similar between arms. Grade 3 and 4 toxicities were sensory neuropathy, diarrhea, nausea, vomiting, neuropathic pain, neutropenia, thrombocytopenia, and hand-foot syndrome.
Note. For complete descriptions of the regimens, see Oxaliplatin 85 mg/m 2 IV over two hours, day 1 LV 200 mg/m 2 IV over two hours, days 1 and 2 5-FU 400 mg/m 2 IV bolus, then 600 mg/m 2 IV over 22 hours, days 1 and 2 Repeat every two weeks.
Oxaliplatin 100 mg/m 2 IV over two hours, day 1 LV 200 mg/m 2 IV over two hours, day 1 5-FU 400 mg/m 2 IV bolus, then 2.4-3 g/m 2 over 46 hours, continuous infusion Repeat every two weeks.
Oxaliplatin 85 mg/m 2 IV over two hours, day 1 LV 175 mg/m 2 IV over two hours, day 1 5-FU 400 mg/m 2 IV bolus, then 2.4-3 g/m 2 over 46 hours, continuous infusion Repeat every two weeks. Delayed diarrhea occurs around the same time as the blood count nadir and, depending on severity, can lead to febrile neutropenia and sepsis. Nurses are in a strategic position to ensure that patients take antidiarrheal medications as instructed (e.g., loperamide by protocol rather than label indication). In one regimen, diarrhea is treated with an initial 4 mg dose at onset followed by a 2 mg dose every two hours, continuing for 12 hours after the diarrhea ceases. At night, patients are instructed to take a 4 mg dose at bedtime, then resume the 2 mg dose on awakening. Patients or athome caregivers must be able and willing to monitor temperature using a thermometer and notify a nurse or physician when diarrhea does not stop in 24 hours, if the temperature rises above 101ºF, if nausea and vomiting occur and do not resolve with antiemetics within 24 hours, and if any other side effect occurs that does not resolve within 24 hours. Guidelines for the management of chemotherapy-induced diarrhea initially established in 1998 can be used as a basis for patient and family education (Wadler et al., 1998) .
Hand-Foot Syndrome
Palmar-plantar erythrodysesthesia (PPE), occurs in as many as 56% of patients receiving capecitabine, 34% receiving protracted continuous infusions of 5-FU, and 13% receiving IV bolus 5-FU/LV. PPE appears to be caused by the crushing of deep capillaries in the soles of the feet and palms of the hands, which causes an inflammatory response mediated by cyclo-oxygenase-2 (COX-2). The risk of PPE is increased by exposure to heat (e.g., warm shower, whirlpool), which dilates the capillaries, and by repetitive pressure on the hands or feet (e.g., chopping vegetables, jogging). Signs and symptoms of PPE occur as the inflammatory response intensifies. The first sensation is tingling, followed by erythema of the palms of the hands or soles of the feet, and, finally, edema, pain, and, if the drug is continued, blister formation, desquamation, scarring, and re-epithelialization. PPE grading scales are shown in Table  6 . Some evidence indicates that PPE may be prevented by celecoxib, a COX-2 inhibitor (Lin, Morris, & Ayers, 2002) .
Neurotoxicity
Neurotoxicity is a cumulative dose-limiting toxicity associated with oxaliplatin that can be divided into two types: (a) acute, lasting less than 14 days and often induced by cold, and (b) chronic or persistent, lasting more than 14 days with median onset at a cumulative dose of 800 mg/m 2 . Acute neurosensory syndrome is common, with an incidence of more than 90%, and is a nonlife-threatening side effect related to peripheral nerve hyperexcitability. It is manifested by paresthesias or dysesthesias, which often are precipitated by exposure to cold, such as reaching into the freezer to remove a food item. Patients should be told that this sensation may occur and should be taught to minimize its likelihood by avoiding exposure to cold for as long as five days after drug administration. Figure 4 provides specific patient-teaching points.
Patients also may experience muscle cramping or spasms in the jaw, hand, or forearm (Wilkes, 2002) . A cramp takes longer than normal to resolve because of delayed relaxation of the muscle's action potential (Grolleau et al., 2001 ). Jaw spasm is common, especially on opening the jaw to ingest food; even when it lasts only a moment, it is intensely painful. Less commonly, patients may experience pharyngolaryngeal dysesthesia, the sensation of being unable to pass air into the lungs or swallow. Dysesthesia is sensed in the back of the throat. If it is unexpected, the patient may panic, thereby heightening the distress of the event. Nurses should assess patients if this occurs and differentiate a pharyngolaryngeal dysesthesia episode from a hypersensitivity reaction. A hypersensitivity reaction will manifest a decreased oxygen saturation level because airflow is decreased during an allergic response. A pharyngolaryngeal dysesthesia episode creates the feeling of airway obstruction for a patient with no actual loss of airflow; therefore, oxygen saturation levels remain near baseline.
Nursing interventions include apprising patients and their families that these events may occur and are not life threatening, teaching them measures to avoid exposure to cold, and providing emotional support. Slowing infusion time to as long as six hours lowers the peak serum drug concentration by 32% and may reduce or eliminate the occurrence of acute neuropathy (Sorich, Taubes, Wagner, & Hochster, 2004) .
In contrast, chronic or persistent sensory neuropathy is a more severe problem and, if the drug is continued in the face of grade 3 or 4 toxicity, can involve the motor peripheral nervous system. This type of neuropathy usually occurs well after the patient has demonstrated a response to oxaliplatin-containing chemotherapy, with a peak onset at a cumulative dose of 800 mg/m 2 . Platinum compounds, including oxaliplatin, affect the large-fiber nerves, which are responsible for sensing vibration, position, and the spatial relationship of the body (i.e., the relative position of body parts). An example of largefiber nerve function is observed in driving a car: the experienced driver does not look at the pedals when shifting or braking but moves the feet automatically. This sense is compromised as oxaliplatin-induced peripheral neuropathy worsens.
Nurses must perform a simple pretreatment neurologic examination and alert the physician before administering oxaliplatin if a patient has reached established toxicity levels, as well as document the patient's signs, symptoms, and functional ability. Neurologic damage first affects the longest axons, those stretching to the tips of the toes and fingers. Paresthesias progress in a stocking-glove distribution; that is, they start at the tips of the fingers or toes, move proximally to the hands and feet, then continue to the wrist and calf. Nurses should assess the level of functional impairment from paresthesia or dysesthesia-what skill the patient has lost, such as buttoning a shirt, working a zipper, or cutting food with a knife and fork. As patients return for treatment every other week for FOLFOX4, nurses should assess whether symptoms are progressing. If function is impaired, the physician or nurse practitioner should perform a full neurologic examination. Interference with function that persists between cycles necessitates a dose reduction in oxaliplatin to 65 mg/m 2 , from 85 mg/m 2 in the FOLFOX4 regimen. If symptoms interfere with activities of daily living, such as walking or working, the drug should be discontinued (Sanofi-Synthelabo, 2004) . Safety and the prevention of disabling neuropathy are overriding priorities. Ongoing nursing assessment and documentation of findings help guide the patient and team to balance the drug's toxicity against its benefit. Fortunately, most chronic, persistent neuropathy appears after an initial response has been obtained, when the risk versus benefit is clearer. In addition, options such as changing to infusional 5-FU/LV may permit a drug holiday and temporary regression of neuropathy before reintroduction of oxaliplatin-containing regimens. Quality of life is important, and measures to enhance comfort include pharmacologic and nonpharmacologic strategies. For painful neuropathy, gabapentin is the drug of choice, with doses beginning at 300 mg per day, sometimes requiring titration up to a total dose of 3,600 mg per day (Backonja et al., 1998; Paice, 2003 Teach patient to stop laxatives. Acute: atropine 0.25-1 mg IV push Delayed: loperamide 4 mg, then 2 mg every two hours and continuing 12 hours after diarrhea stops; replace fluids and electrolytes; teach patient to gradually change position to reduce orthostasis and to come in for evaluation and hydration for persistent diarrhea or orthostasis.
Teach patient to self-assess palms of hands and soles of feet for redness, pain, or swelling and to stop drug and report to healthcare professionals if this occurs; avoid constrictive shoes, gloves, and clothing; avoid repetitive pressure on soles and palms (e.g., jogging, cutting vegetables); use emollients to keep skin soft; avoid hot showers, whirlpools, or water when doing dishes; take pyridoxine if ordered; assess need for assistance at home; and take acetaminophen for pain.
Teach patient that paresthesias may occur in hands, feet, and hypopharynx. Patients should avoid exposure to cold for one to five days after drug is given. Trial of calcium and magnesium prior to and after oxaliplatin if ordered
Assess for signs and symptoms of peripheral neuropathy at each visit. Teach patient to report worsening paresthesias, difficulty with walking or activities of daily living. Assess risk for injury and institute safety precautions with patient in the home. If it interferes with function (grade 2), discuss dose reduction with physician. If it interferes with activities of daily living (grade 3), hold the drug. Discuss strategies to manage neuropathic pain if it occurs: pharmacologic (e.g., gabapentin, opioids) and nonpharmacologic (e.g., hydrotherapy, acupuncture).
Assess for signs and symptoms of allergic reaction (e.g., hives, rash, fever, itch, anxiety, feeling cold). Stop drug, stabilize, and administer acetaminophen, diphenhydramine, dexamethasone, epinephrine, or aminophylline as ordered. If the reaction is localized, extend next infusion to six hours to lower peak serum level by 32%, and premedicate with H 2 antagonist, steroid, and diphenhydramine.
Assess blood pressure prior to each treatment, between visits, and for as long as three months after treatment with bevacizumab has stopped. Teach patient self-administration of antihypertensive medications.
Teach patient to report signs and symptoms of thrombosis, including new swelling, pain, skin warmth, and/or change in color (e.g., erythema, mottling) on the legs or thighs; new onset pain in the abdomen; dyspnea or shortness of breath; rapid heartbeat; chest pain or pressure that may signal a pulmonary embolism; and any changes in vision, new onset of severe headache, lightheadedness, or dizziness.
Assess skin integrity, wound healing, and signs and symptoms of bleeding, including neurologic status. Teach patient that surgery should not be performed within 28 days of the last drug dose. Teach patient that epistaxis may occur, how to apply pressure, and to report epistaxis that is not controlled or any other bleeding.
Teach patient that, rarely, gastrointestinal perforation may occur and to report right away any abdominal pain associated with nausea and constipation.
Teach patient to limit sun exposure, wear sunscreen and hats, practice skin hygiene, report infections, and avoid using topical hydrocortisone. Treat infection with topical clindamycin gel, oral cephalexin as ordered by the physician, or other topical skin antimicrobial ointment. therapy, relaxation, massage, hydrotherapy, and acupuncture (Visovsky, 2003) . Nursing assessment priorities for patients at risk for developing chronic, persistent sensory neuropathy are shown in Figure 5 . However, many patients with these symptoms have significant responses and do not wish to stop drug administration. Investigators have explored different options, from preventing or minimizing the severity of neuropathy to alternating therapies with a holiday from oxaliplatin exposure so that peripheral nerves can recover (Andre et al., 2003; Gamelin, Gamelin, Bossi, & Quasthoff, 2002) . Oxaliplatin neuropathy appears to be related to an acquired channelopathy (an altered channel for electrolytes, such as calcium, to pass during the conduction of a nervous impulse) with increased neuronal excitability (Gamelin et al., 2002; Wilson et al., 2002) . To prevent or minimize the severity of acute neuropathy, Gamelin et al. (2004) administered 1 g each of magnesium and calcium 15 minutes before and after oxaliplatin administration. Neuropathy of any grade was reduced significantly in the treated group (20% versus 45% in the control group), and grade 3 neurotoxicity also was reduced, with 7% of patients in the treated group versus 26% in the control group developing grade 3 or 4 toxicity (Gamelin et al., 2004) . In addition, Pederiva and Caspar (2004) found that prophylactic administration of a magnesium and calcium infusion was a safe and effective method to prevent oxaliplatin-induced acute sensory neuropathy. Findings regarding chronic sensory neuropathy are inconclusive.
Allowing peripheral nerves to recover by employing an alternating-therapy schema was studied in the OPTIMOX trial in patients with advanced colon cancer. The trial was undertaken to establish whether FOLFOX7 (see Figure 6 ) could be given for six cycles, then alternated with 5-FU/LV infusion alone for 12 cycles (or fewer if progression occurred, requiring oxaliplatin reintroduction), followed by reinstitution of FOLFOX7 for six cycles, thereby allowing time between regimens for regression of cumulative or persistent neuropathy, compared to the other treatment arm of FOLFOX4, which treated to failure. Andre et al. (2003) reported that the overall response rates and median times to disease control for FOLF-OX7 versus FOLFOX4 were comparable (63% versus 60% and 12.3 months versus 10.3 months, respectively). Of patients receiving FOLFOX4, 18.3% had grade 3 toxicity, compared with 10.8% of patients receiving FOLFOX7 (Andre et al., 2003) . De Gramont et al. (2004) reported that further studies using a lower dose of oxaliplatin are planned. Andre, Maindrault-Goebel, et al. (2004) established an OPTIMOX2 trial that adds celecoxib, a COX-2 inhibitor, during FOLFOX7 treatment followed by a chemotherapy-free interval. Celecoxib has activity in preventing colon cancer and in one study reduced neuropathy (Agafitei et al., 2004) . Only 2% of patients in the treatment arm receiving FOLFOX7 plus celecoxib developed grade 3 neurotoxicity; unfortunately, the response rate was only 39% compared with more than 50% in the GRADE DESCRIPTION MANAGEMENT Interrupt therapy until PPE resolves to grade 0-1. With second appearance, interrupt treatment until PPE is resolved to grade 0-1, then resume at a 75% dose. At third appearance, interrupt treatment until PPE is resolved to grade 0-1, then resume at a 50% dose. With fourth appearance, discontinue treatment permanently. Give acetaminophen for pain.
Interrupt therapy until PPE resolves to grade 0-1, then resume at a 75% dose. With second appearance, interrupt treatment until PPE is resolved to grade 0-1, then resume at a 50% dose. At third appearance, discontinue treatment permanently.
Note. Some data are based on information from Roche Pharmaceuticals, 2003.
Teach patient that acute, cold-induced neuropathy may occur and is self-limiting but not lifethreatening. Instruct patient to avoid exposure to cold if possible and to warm area if cold-induced symptoms occur.
• Wear gloves if reaching into a refrigerator or freezer or when going outside.
• Wear a scarf wrapped around the neck and mouth to prevent inspiration of cold air that could cause pharyngolaryngeal dysesthesia.
• If fingers or toes become cold and paresthesias occur, rinse extremity under warm water. Teach patient to report neuropathy that persists and interferes with function or ability to care for self.
FIGURE 4. PATIENT TEACHING FOR ACUTE NEUROSENSORY NEUROPATHY
Assess patient's neurologic patterns prior to chemotherapy and any change in functional ability.
• Compare to baseline.
• If alteration in function persists between treatment cycles, have physician or nurse practitioner perform a more in-depth neurologic examination, as dose reduction is recommended if functional impairment exists.
• If the patient is impaired in ability to perform activities of daily living, then the drug should be held.
Assess safety and need for occupational or physical therapy.
• 
FIGURE 5. NURSING ASSESSMENT FOR CHRONIC, PERSISTENT SENSORY NEUROPATHY
FOLFOX7 arm in OPTIMOX1. This suggests that pharmacokinetic studies of the combination of celecoxib and FOLFOX need to be performed (Andre, MaindraultGoebel, et. al., 2004) .
Ongoing studies show that a majority of patients who develop chronic neuropathy see resolution of the condition following the conclusion of their treatment. In the MOSAIC adjuvant clinical trial (N = 2,246), 12.4% of patients developed grade 3 neuropathy during treatment. Of these patients with grade 3 neurotoxicity, 99% had resolution within a year (de Gramont et al., 2003; Hickish et al., 2004) .
Two specific nursing issues relating to oxaliplatin are extravasation management and delayed hypersensitivity.
Extravasation
Oxaliplatin is categorized as a severe irritant. Yet a number of reports have described case examples, which have led many institutions to classify it as a vesicant agent (Wilkes & Barton-Burke, 2005) . Baur, Kienzer, Rath, and Dittrich (2000) described the course of extravasation of oxaliplatin leading to tissue necrosis that necessitates surgical repair. Kennedy, Donahue, Hoang, and Boland (2003) described the extravasation of oxaliplatin into the antecubital fossa, which resulted in muscle necrosis and fibrosis requiring extensive physical therapy to restore function. Kretzschmar et al. (2003) found less severe sequelae: erythema and induration, followed by the formation of a nodule as demonstrated by magnetic resonance imaging and persisting for as long as nine months. In addition, they found that anti-inflammatory drugs and the early administration of dexamethasone positively influenced outcome, and no patients required plastic surgery. In addition, anecdotal reports have indicated tissue sloughing when the drug extravasates from an implanted port.
To put this potentially devastating effect in perspective, in more than 30,000 cycles of peripherally administered oxaliplatin, reports of serious extravasation have been relatively few (Baur et al., 2000; Sanofi-Synthelabo, 2004; Sorich et al., 2004) . However, if drug extravasation is suspected, Oncology Nursing Society guidelines (Brown et al., 2001) should be followed: Stop administration and aspirate any remaining drug from the site. High-dose dexamethasone may be helpful, if it has not been administered already as an antiemetic agent. Avoid the application of cold, and apply heat for comfort. Pain may be relieved by nonsteroidal anti-inflammatory drugs and diclofenac gel. Because of the significant effect on patient quality of life and the strategic position of nurses to prevent and minimize harmful sequelae, this is a highpriority area for nursing research. In addition, when oxaliplatin is administered through a peripheral IV line, slowing the infusion and increasing the volume of dilution to 500 ml 5% dextrose can decrease burning in a vessel that has been damaged by prior infusions. Further measures to increase local comfort are the application of warm compresses and a topical 1% hydrocortisone cream to the area (Sorich et al.) .
Hypersensitivity Reactions
Although rare, delayed hypersensitivity reactions may occur with oxaliplatin, usually during cycles 9-11. Severity can range from vague nausea when none was experienced previously to localized rash or full-blown anaphylaxis. Grade 1 and 2 signs and symptoms include hives, rash, fever, pruritus, and anxiety, which respond to diphenhydramine; grade 3 and 4 symptoms present with shortness of breath, stridor, laryngeal edema, and bronchospasm, requiring prompt emergency intervention. If hypersensitivity is suspected, the nurse should stop the drug, stabilize the patient, and be prepared to administer rescue drugs, such as dexamethasone, diphenhydramine, epinephrine, and aminophylline, as ordered or according to the institutional standard of care. Using preparatory regimens is another strategy to prevent hypersensitivity reactions and subsequently permit continuation of therapy. Thomas, Quinn, Schuler, & Grem (2003) reviewed the incidence and management of hypersensitivity and idiosyncratic reactions to oxaliplatin and found that patients with mild to moderate hypersensitivity could be pretreated successfully with steroids and H1 and H2 histamine antagonists prior to subsequent cycles. However, they suggested no rechallenge to patients with severe hypersensitivity reactions, such as anaphylaxis. In a retrospective review of patient experiences, Dold et al. (2002) found an 8% incidence of hypersensitivity reactions. They reported successful management and retreatment for mild or moderate hypersensitivity reactions using a longer infusion time of six hours (lowers peak serum level by 32%) and premedication with a steroid and H1 and H2 histamine antagonists. A similar delayed hypersensitivity reaction has been described, and successful desensitization protocols have been employed by Goldberg, Confino-Cohen, Fishman, Beyth, and Altaras (1996) .
Decreased Wound Healing, Bleeding, Bowel Perforation, Hypertension, and Thrombosis
Patients receiving bevacizumab may experience other toxicities, as discussed below.
Decreased wound healing and bleeding: Angiogenesis is key to wound healing; bevacizumab, in neutralizing VEGF, also decreases wound healing and increases risk of dehiscence. Patients should not receive bevacizumab within 28 days of surgery because the drug's half-life is 20 days (Genentech, Inc., 2004) . Two patterns of bleeding may occur rarely: minor hemorrhage, such as mild epistaxis, and serious hemorrhage. Of note, hemorrhage (pulmonary, hemoptysis) occurred when the drug was being studied in patients with lung cancer, with a higher incidence (31% in a small study) in patients with squamous cell histology. Many of the patients appeared to bleed from a cavitation or area of necrosis in the pulmonary tumor (Wilkes & Barton-Burke, 2005) . Central nervous system bleeding was not evaluated because patients with brain metastases were excluded from the study after a cerebral hemorrhage in a patient with brain metastases (Genentech, Inc.) . Patients experiencing grade 3 or 4 bleeding from any cause were similar in both arms (Hurwitz et al., 2004) . However, 6% of patients in the IFL plus placebo arm experienced gastrointestinal bleeding compared with 24% in the bevacizumab plus IFL arm (Genentech, Inc.) . Mild epistaxis occurs in about 35% of patients receiving bevacizumab plus IFL, compared with 10% in the IFL plus placebo arm (Genentech, Inc.) . Epistaxis, if it occurs, is controlled easily with pressure. Patients should be taught that epistaxis may occur, how to apply pressure, and to call a healthcare provider immediately if bleeding occurs elsewhere or if epistaxis does not resolve with pressure.
Gastrointestinal perforation: Rarely, patients may develop gastrointestinal perforation, 
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which sometimes is fatal. It may be associated with intra-abdominal abscesses and may occur at variable times during treatment. The incidence in preapproval studies was 1.5%, compared with 0.0% in the bolus IFL plus placebo arm (Hurwitz et al., 2004) . Presenting symptoms were abdominal pain associated with nausea and constipation, so patients should be taught to report this. Colonoscopy has a similar risk of gastrointestinal perforation, so the drug should be stopped 28 days before a planned colonoscopy.
Hypertension: Patients receiving bevacizumab plus IFL had a statistically significant increased incidence of grade 3 or 4 hypertension (10.9%) compared with the IFL plus placebo (2.3%) arm (Hurwitz et al., 2004) . Hypertension was managed easily with oral antihypertensive agents, such as angiotensin-converting enzyme inhibitors, diuretics, or calcium channel blocking agents. Nurses should monitor blood pressure before treatment, between treatments, and for as long as three months after treatment is finished and teach patients self-administration of antihypertensive medications when they are prescribed.
Thrombosis: Thrombosis occurred in both treatment arms: 19.4% in the bevacizumab plus IFL arm compared with 16.2% in the IFL plus placebo arm, but the difference was not significant (Hurwitz et al., 2004) . More patients receiving IFL plus placebo experienced pulmonary embolus (5.1%) compared with 3.6% in the bevacizumab plus IFL arm. Deep vein thrombosis occurred in 8.9% of patients in the bevacizumab plus IFL arm compared with 6.3% in the placebo plus IFL arm, again not statistically significant. Nurses should assess for and teach patients to report signs and symptoms of thrombosis: new swelling, pain, skin warmth, and/or change in color (e.g., erythema, mottling) on the legs or thighs; new onset pain in the abdomen; dyspnea or shortness of breath, rapid heartbeat, and chest pain or pressure that may signal a pulmonary embolism; any changes in vision; new onset of severe headache; lightheadedness; or dizziness.
Acneiform Rash
Cetuximab, an epidermal growth factor inhibitor, has toxicity in the epidermis of the skin, and rash occurs in most patients. Fourteen percent of patients reported a grade 3 rash; in clinical studies, 1.6% of patients discontinued treatment because of skin rash (ImClone, Inc., and Bristol-Myers Squibb Co., 2004) . The rash is sterile and suppurative, with multiple follicular or pustular lesions that appear during the first two weeks of therapy on the face, upper chest, and back but in some cases extend to the arms (see Figure 7) . The rash resolves when treatment is stopped, without scar formation. However, in 50% of patients, it takes longer than 28 days to resolve. Seven percent of patients reported dry skin, which may be associated with fissures and, in some cases, inflammation and infection such as blepharitis and cellulitis. Infection can be treated with topical clindamycin or oral antibiotics such as cephalexin 250 mg twice a day for three days, followed by 250 mg every day for seven days (Wilkes & Barton-Burke, 2005) . Teach patients not to use topical corticosteroid cream and to report significant rash, skin discomfort, or exudates. Nurses should assess the extent of rash and presence of infection. If the rash is severe, the drug should be held for one or two weeks; once the rash resolves, the dose is reduced on and after the second occurrence. If the rash does not resolve, the drug should be stopped. Although further studies are needed, a correlation appears to exist between the emergence of skin rash toxicity and tumor response (Cunningham et al., 2003) .
Conclusions
This is an exciting time for patients with colon cancer and practitioners because many new treatment options are being introduced for early and advanced disease as a result of carefully planned, progressive clinical trials. New pharmacologic advances such as the FOLFOX4 regimen when used in the adjuvant setting have resulted in improved disease-free survival at three years, with overall survival data maturing, and patients with metastatic disease are surviving longer with combination chemotherapy and molecular targeted therapy. Nurses play a strategic role in successful integration of new advances into standard practice and often are the pioneers of new or improved patient care interventions designed to enhance patient access to clinical trials, patient and family understanding of therapeutic regimens, identification and management of treatmentrelated side effects, and documentation of patient responses. The information provided in this article will help nurses to translate study findings into patient and family interactions and incorporate associated patient care protocols into practice.
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